{"filing":{"accession_number":"0001683168-26-005497","cik":"0001787740","ticker":"VBIO","company_name":"Valion Bio, Inc.","form":"8-K","filing_date":"2026-07-14","report_date":null,"primary_document":"valion_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1787740/000168316826005497/valion_8k.htm"},"events":[{"id":17742,"run_id":15907,"accession_number":"0001683168-26-005497","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release discloses multiple strategic business developments: continued government engagement with BARDA, NIAID, AFRRI, and DoW on ARS preparedness; a 200-fold manufacturing scale-up at Velocity Bioworks; and planned expansion into oncology supportive care. These are operational and strategic milestones rather than financial results, M\u0026A activity, or governance changes. While the filing is under Item 7.01 (Regulation FD Disclosure) rather than a dedicated 8-K item, the substance reflects material operational progress across regulatory, manufacturing, and clinical development initiatives that would affect a reasonable investor's assessment of the company's strategic positioning and value creation pathways.","company_name":"Valion Bio, Inc.","ticker":"VBIO","filing_date":"2026-07-14","form":"8-K","submitted_at":null,"items":[{"id":16331,"accession_number":"0001683168-26-005497","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release discloses multiple strategic business developments: continued government engagement with BARDA, NIAID, AFRRI, and DoW on ARS preparedness; a 200-fold manufacturing scale-up at Velocity Bioworks; and planned expansion into oncology supportive care. These are operational and strategic milestones rather than financial results, M\u0026A activity, or governance changes. While the filing is under Item 7.01 (Regulation FD Disclosure) rather than a dedicated 8-K item, the substance reflects material operational progress across regulatory, manufacturing, and clinical development initiatives that would affect a reasonable investor's assessment of the company's strategic positioning and value creation pathways.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T11:46:41.439094+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16331,"accession_number":"0001683168-26-005497","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release discloses multiple strategic business developments: continued government engagement with BARDA, NIAID, AFRRI, and DoW on ARS preparedness; a 200-fold manufacturing scale-up at Velocity Bioworks; and planned expansion into oncology supportive care. These are operational and strategic milestones rather than financial results, M\u0026A activity, or governance changes. While the filing is under Item 7.01 (Regulation FD Disclosure) rather than a dedicated 8-K item, the substance reflects material operational progress across regulatory, manufacturing, and clinical development initiatives that would affect a reasonable investor's assessment of the company's strategic positioning and value creation pathways.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T11:46:41.439094+00:00","company_name":"Valion Bio, Inc.","ticker":"VBIO","filing_date":"2026-07-14"}]}